Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program

The work, led by Roswell Park’s Katerina Gurova, PhD, and Sethera CEO Karsten Eastman, PhD, could open a path toward targeted options for patients with aggressive tumors that have limited treatment choices